PHOENIX PLUS WORST OF - MULTI UNDERLYINGS

PHOENIX PLUS WORST OF - MULTI UNDERLYINGS Share Price

Certificat

0158SG

CH0520888162

Market Closed - Swiss Exchange 07:49:05 16/07/2020 pm IST
55.3 ^USD	+24.83%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart REGENERON PHARMACEUTICALS, INC.

Chart PHOENIX PLUS WORST OF - MULTI UNDERLYINGS

Latest news about REGENERON PHARMACEUTICALS, INC.

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	05:46pm	PR
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea	15/06	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing	14/06	MT
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050	12/06	MT

More news

Static data

Product type	Other Certificates
Buy / Sell	CALL
Underlying	REGENERON PHARMACEUTICALS, INC.
Issuer	Société Générale
	0158SG
ISIN	CH0520888162
Date issued	18/02/2020
Maturity	10/02/2025 (240 Days)
Parity	1 : 1
Emission price	89.75 $
Emission volume	N/A
Settlement	cash
Currency	USD

Technical Indicators

Highest since issue	91.05 $
Lowest since issue	27.7 $
Spread	10 $
Spread %	0.98%

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

More about the company